S Zouaoui1, A Darlix2, V Rigau3, H Mathieu-Daudé4, F Bauchet4, F Bessaoud5, P Fabbro-Peray6, B Trétarre5, D Figarella-Branger7, L Taillandier8, H Loiseau9, L Bauchet10. 1. Department of neurosurgery, Gui-de-Chauliac hospital, CHU Montpellier, 34295 Montpellier cedex 5, France; Inserm U 1051, INM Montpellier, 34091 Montpellier, France. 2. Inserm U 1051, INM Montpellier, 34091 Montpellier, France; Department of medical oncology and department of radiation oncology, ICM, 34298 Montpellier cedex 5, France. 3. Department of pathology, Gui-de-Chauliac hospital, CHU Montpellier, 34295 Montpellier cedex 5, France. 4. Department of epidemiology, French Brain Tumor Database, GNOLR, Registre des Tumeurs de l'Hérault, ICM, 34298 Montpellier cedex 5, France. 5. Registre des Tumeurs de l'Hérault, ICM, 34298 Montpellier cedex 5, France. 6. Department of Biostatistics, IURC, 34095 Montpellier, France; BESPIM, CHU Nîmes, 30029 Nîmes, France. 7. Inserm U 911, department of neuropathology, hôpital de La Timone, université de la Méditerranée, 13005 Marseille, France. 8. Department of neuro-oncology, CHU Poitiers, 86021 Poitiers cedex, France. 9. Department of neurosurgery, CHU Bordeaux, 33000 Bordeaux, France. 10. Department of neurosurgery, Gui-de-Chauliac hospital, CHU Montpellier, 34295 Montpellier cedex 5, France; Inserm U 1051, INM Montpellier, 34091 Montpellier, France. Electronic address: l-bauchet@chu-montpellier.fr.
Abstract
PURPOSE: This work describes the clinical epidemiology and pathology for patients undergoing surgery for newly diagnosed meningiomas in France between 2006 and 2010. METHODS: The methodology is based on a multidisciplinary national network previously established by the French Brain Tumor DataBase (FBTDB) (in French: Recensement national histologique des tumeurs primitives du système nerveux central [RnhTPSNC]), and the active participation of the scientific societies involved in neuro-oncology in France. RESULTS: From 2006 to 2010, 13,038 incident cases of meningioma with histological validation were identified and analyzed (9769 women, 3269 men, resection 98.2%, cryopreservation 20.5%). For each histological subtype of meningioma (meningothelial, fibrous, transitional, psammomatous, angiomatous, rare variety, microcystic, secretory, lymphoplasmacyte-rich, clear-cell, chordoid, rhabdoid, metaplastic, atypical, papillary, anaplastic and not otherwise specified), number of cases, sex, median age, cryopreservation and surgery were reported. Among the various histological subtypes, atypical meningioma (grade II) slightly, but significantly, increased after 2007. Headache, sensory-motor impairments and seizures were the most frequent clinical symptoms. Time between the first clinical symptom and surgery ranged from 0 to 314 months, and was <3 months in 37% of cases. At the time of surgery, 9% of patients were asymptomatic. DISCUSSION/ CONCLUSION: Given the number of meningiomas not histologically-validated, we can estimate that the gross incidence rate for meningiomas operated in France is about 4.2 per 100,000 person/year. To our knowledge, this work is the most important study evaluating the different subtypes of meningiomas and it validates the relevance of histological databases for central nervous system tumors.
PURPOSE: This work describes the clinical epidemiology and pathology for patients undergoing surgery for newly diagnosed meningiomas in France between 2006 and 2010. METHODS: The methodology is based on a multidisciplinary national network previously established by the French Brain Tumor DataBase (FBTDB) (in French: Recensement national histologique des tumeurs primitives du système nerveux central [RnhTPSNC]), and the active participation of the scientific societies involved in neuro-oncology in France. RESULTS: From 2006 to 2010, 13,038 incident cases of meningioma with histological validation were identified and analyzed (9769 women, 3269 men, resection 98.2%, cryopreservation 20.5%). For each histological subtype of meningioma (meningothelial, fibrous, transitional, psammomatous, angiomatous, rare variety, microcystic, secretory, lymphoplasmacyte-rich, clear-cell, chordoid, rhabdoid, metaplastic, atypical, papillary, anaplastic and not otherwise specified), number of cases, sex, median age, cryopreservation and surgery were reported. Among the various histological subtypes, atypical meningioma (grade II) slightly, but significantly, increased after 2007. Headache, sensory-motor impairments and seizures were the most frequent clinical symptoms. Time between the first clinical symptom and surgery ranged from 0 to 314 months, and was <3 months in 37% of cases. At the time of surgery, 9% of patients were asymptomatic. DISCUSSION/ CONCLUSION: Given the number of meningiomas not histologically-validated, we can estimate that the gross incidence rate for meningiomas operated in France is about 4.2 per 100,000 person/year. To our knowledge, this work is the most important study evaluating the different subtypes of meningiomas and it validates the relevance of histological databases for central nervous system tumors.
Authors: Adelheid Woehrer; Ching C Lau; Daniela Prayer; Luc Bauchet; Myrna Rosenfeld; David Capper; Paul G Fisher; Marcel Kool; Martin Müller; Johan M Kros; Carol Kruchko; Joseph Wiemels; Margaret Wrensch; Heather E Danysh; Sonia Zouaoui; Julia E Heck; Kimberly J Johnson; Xiaoyang Qi; Brian P O'Neill; Samina Afzal; Michael E Scheurer; Matthew N Bainbridge; Darryl Nousome; El Mustapha Bahassi; Johannes A Hainfellner; Jill S Barnholtz-Sloan Journal: Clin Neuropathol Date: 2015 Jan-Feb Impact factor: 1.368
Authors: Jean-Michel Lemée; Marco V Corniola; Michele Da Broi; Holger Joswig; David Scheie; Karl Schaller; Eirik Helseth; Torstein R Meling Journal: Sci Rep Date: 2019-04-11 Impact factor: 4.379
Authors: Radhika Dhamija; Steven M Weindling; Alyx B Porter; Leland S Hu; Christopher P Wood; Joseph M Hoxworth Journal: Neurol Clin Pract Date: 2018-06
Authors: Jonas Nilsson; Georg Holgersson; Tobias Carlsson; Roger Henriksson; Stefan Bergstrom; Michael Bergqvist Journal: World J Oncol Date: 2016-09-03